Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

10 Nov 2016 07:00

RNS Number : 8050O
Devro PLC
10 November 2016
 

This announcement contains inside information

10 November 2016

 

Devro plc

 

Trading Update

 

Devro plc ("the Group"), one of the world's leading manufacturers of collagen products for the food industry, today issues a trading update for the period 1 July 2016 to the current date ("the period").

Trading summary for the period and 2016 outlook

Sales volume trends were broadly similar to those experienced in the first half, enhanced by improvements in Russia and South East Asia, but impacted by further reductions in Latin America due to the previously highlighted issues, which are being addressed, related to the transformation of our global manufacturing footprint. Combined, these factors have had an adverse impact on margins, offset by further benefits from lower input costs and foreign exchange. As a result, the Board's full year expectations for underlying operating profit* remain unchanged.

Our new factories in the US and China are now integrated into the Group's manufacturing base, completing the transformation of our global manufacturing footprint. As expected, in the second half £8 million of exceptional costs related to these capital investment projects have been incurred, including £1 million of additional foreign exchange movements. There will be no further exceptional costs related to these capital investment projects.

2017 and beyond

Based on current trends, sales volumes in 2017 are now expected to be approximately 10% lower than previously anticipated, which will result in an under-utilisation of available capacity. Actions are being taken to rebalance the use of capacity across our global manufacturing base. The under-utilisation is expected to have a further adverse impact on margins.

The Board has decided to accelerate and implement more extensively the next stage of the Group's strategic development, focusing on growing sales through improved commercial capabilities, introducing the next generation of differentiated products, and further improving manufacturing efficiencies to reduce unit costs. This improvement project will deliver a fundamentally more competitive position. The benefits will offset the effects of the lower volumes, partially in 2017 and fully in 2018. 

Consequently, the Board now expects underlying operating profit* for 2017 to be lower than previous expectations.

There will be additional costs and capital expenditure associated with the improvement project. Given the nature and scale of the planned actions, these costs will be charged as exceptional items, of which approximately £3 million is expected to be incurred in the final quarter of 2016.

Devro's markets remain attractive. With completion of the capital investment projects the Group now has an excellent manufacturing base and, with the benefits resulting from the improvement project, the Board considers the Group to be well positioned to grow revenue and profits over the long term.

* Underlying operating profit is defined as operating profit before exceptional items

 

ENDS

 

 

Contacts:

 

Devro plc

Peter Page

Chief Executive

Tel: 020 7182 4960

Rutger Helbing

Group Finance Director

Tel: 020 7182 4960

 

FTI Consulting

Richard Mountain / Nick Hasell

Tel: 020 3727 1340

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFSIEFUFMSEDF
Date   Source Headline
1st Apr 20221:00 pmRNSBlock Listing Application
31st Mar 20229:57 amRNSDirector/PDMR Shareholding
25th Mar 20223:51 pmRNSAnnual Report & Accounts 2021 & Notice of 2022 AGM
2nd Mar 20227:00 amRNSFULL YEAR RESULTS
21st Jan 20223:17 pmRNSDirector/PDMR Shareholding
20th Jan 20225:39 pmRNSDirector/PDMR Shareholding
19th Jan 20225:23 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSTrading update
16th Dec 202112:14 pmRNSHolding(s) in Company
23rd Nov 20217:00 amRNSTrading Update
2nd Nov 20217:00 amRNSDirectorate Changes
29th Sep 20218:00 amRNSNotice of ESG Seminar
24th Aug 20218:48 amRNSHolding(s) in Company
24th Aug 20218:47 amRNSHolding(s) in Company
12th Aug 20215:55 pmRNSHolding(s) in Company
4th Aug 202111:19 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSHalf-year Results
27th Jul 20214:57 pmRNSDirector/PDMR Shareholding
4th Jun 20219:05 amRNSDirector Declaration
5th May 20215:15 pmRNSDirector/PDMR Shareholding
4th May 20215:34 pmRNSDirector/PDMR Shareholding
29th Apr 20215:09 pmRNSResult of AGM
29th Apr 20217:00 amRNSTrading Update
15th Apr 20213:14 pmRNSDirector/PDMR Shareholding
13th Apr 20214:53 pmRNSDirector/PDMR Shareholding
26th Mar 20214:47 pmRNS2020 Annual Report and Notice of AGM
10th Mar 20215:04 pmRNSDirector/PDMR Shareholding
5th Mar 20214:45 pmRNSDirector/PDMR Shareholding
2nd Mar 20217:00 amRNSFULL YEAR RESULTS
20th Jan 20219:29 amRNSDirector/PDMR Shareholding
18th Jan 20217:00 amRNSTrading update
18th Dec 20202:12 pmRNSDirector/PDMR Shareholding
24th Nov 20207:00 amRNSTrading Update
22nd Oct 20207:00 amRNSDirectorate Changes
14th Oct 20207:00 amRNSDirectorate Appointment
7th Oct 202010:16 amRNSDirector/PDMR Shareholding
17th Aug 20207:00 amRNSDirector/PDMR Shareholding
29th Jul 20207:01 amRNSDirectorate Change
29th Jul 20207:00 amRNSHALF YEAR RESULTS
30th Jun 20207:00 amRNSAppointment of Corporate Broker
23rd Jun 20209:23 amRNSHolding(s) in Company
12th Jun 20208:27 amRNSDirector/PDMR Shareholding
15th May 202012:02 pmRNSPrice Monitoring Extension
12th May 202011:06 amRNSDirector/PDMR Shareholding
30th Apr 20202:39 pmRNSResult of AGM
29th Apr 20207:00 amRNSDirectorate Appointment
27th Apr 20204:54 pmRNSPublication of Articles of Association
27th Apr 20209:33 amRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSTrading Update
16th Apr 20204:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.